title: Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study.
abstract: OBJECTIVE
  To evaluate the impact of measures of intraocular pressure (IOP) control on progression of visual field (VF) loss during long-term treatment for open-angle glaucoma (OAG).
  
  
  METHODS
  Longitudinal, randomized clinical trial.
  
  
  METHODS
  We included 607 participants with newly diagnosed OAG.
  
  
  METHODS
  Study participants were randomly assigned to initial treatment with medications or trabeculectomy, and underwent examination at 6-month intervals. Standardized testing included Goldmann applanation tonometry and Humphrey 24-2 full threshold VFs. Summary measures of IOP control during follow-up included the maximum, mean, standard deviation (SD), range, proportion less than 16, 18, 20, or 22 mmHg, and whether all IOP values were less than each of these 4 cutpoints. Predictive models for VF outcomes were based on the mean deviation (MD) from VF testing, and were adjusted for age, gender, race, baseline VF loss, treatment, and time. Each summary IOP measure was included as a cumulative, time-dependent variable, and its association with subsequent VF loss was assessed from 3 to 9 years postrandomization. Both linear mixed models, to detect shifts in MD levels, and logistic models, to detect elevated odds of substantial worsening (≥3 dB), were used.
  
  
  METHODS
  We measured the MD from Humphrey 24-2 full threshold VF tests.
  
  
  RESULTS
  The effect of the summary IOP measures differed between the medicine and surgery groups in models that addressed the continuous MD outcome. After adjustment for baseline risk factors, in the medicine group larger values of 3 IOP control measures-maximum IOP (P = 0.0003), SD of IOP (P = 0.0056), and range of IOP (P<0.0001)-were significantly associated with lower (worse) MD over the 3- to 9-year period. No IOP summary measure was significantly associated with MD over time in the surgery group. The same 3 IOP summary measures were also significantly associated with substantial worsening of MD; however, the effects were similar in both treatment groups. In models predicting inadequate IOP control, consistently significant predictors of higher maximum, SD, and range of IOP included black race, higher baseline IOP, and clinical center.
  
  
  CONCLUSIONS
  These results support considering more aggressive treatment when undue elevation or variation in IOP measures is observed.
authors: Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan 48105, USA. dmusch@umich.edu
authors: David C
authors: DC
authors: Musch
authors: Brenda W
authors: BW
authors: Gillespie
authors: Leslie M
authors: LM
authors: Niziol
authors: Paul R
authors: PR
authors: Lichter
authors: Rohit
authors: R
authors: Varma
references: Ophthalmology. 1996 Jan;103(1):183-5
references: 8628552
references: Health Aff (Millwood). 1988 Spring;7(1):19-32
references: 3360391
references: Am J Ophthalmol. 2000 Oct;130(4):429-40
references: 11024415
references: Arch Ophthalmol. 2007 Aug;125(8):1124-5
references: 17698763
references: Ophthalmology. 2009 Feb;116(2):200-7
references: 19019444
references: Am J Ophthalmol. 2009 Aug;148(2):221-6
references: 19427617
references: Ophthalmology. 2008 Jul;115(7):1123-1129.e3
references: 18082889
references: Ophthalmology. 2007 Nov;114(11):1965-72
references: 17628686
references: Biometrics. 1982 Dec;38(4):963-74
references: 7168798
references: Arch Ophthalmol. 2003 Jan;121(1):48-56
references: 12523884
references: Am J Ophthalmol. 1991 Apr 15;111(4):491-500
references: 2012152
references: Ophthalmology. 1999 May;106(5):997-1004; discussion 1004-5
references: 10328403
references: Ann Intern Med. 1993 Feb 1;118(3):201-10
references: 8417638
references: Arch Ophthalmol. 2004 Apr;122(4):532-8
references: 15078671
references: Ophthalmology. 2006 May;113(5):761-5.e1
references: 16650670
references: Am J Ophthalmol. 2009 Aug;148(2):177-8
references: 19619716
references: Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30
references: 12049575
references: Arch Ophthalmol. 1977 Aug;95(8):1374-7
references: 889512
references: Am J Ophthalmol. 1998 Oct;126(4):498-505
references: 9780094
references: Ophthalmology. 2004 Sep;111(9):1627-35
references: 15350314
references: Ophthalmology. 1996 Apr;103(4):657-63
references: 8618767
references: Am J Ophthalmol. 1993 Aug 15;116(2):176-81
references: 8352302
references: Ophthalmology. 1996 Jan;103(1):186-9
references: 8628553
references: Ophthalmology. 2008 Jun;115(6):927-33
references: 17964655
references: Ophthalmology. 2007 Feb;114(2):205-9
references: 17097736
references: Ophthalmology. 1999 Apr;106(4):653-62
references: 10201583
references: Arch Ophthalmol. 2000 Sep;118(9):1187-94
references: 10980763
references: Am J Ophthalmol. 2008 Feb;145(2):336-42
references: 18222194
references: Arch Ophthalmol. 2007 Aug;125(8):1010-3
references: 17698746
references: Am J Ophthalmol. 2007 Dec;144(6):901-907
references: 17919446
references: Am J Ophthalmol. 2000 Sep;130(3):274-9
references: 11020404
references: Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2613-20
references: 12766064
references: Arch Ophthalmol. 2002 Oct;120(10):1268-79
references: 12365904